Company Overview and News

Tribune, Rand to pay out $16m

Closely-linked mining companies Tribune Resources and Rand Mining will empty their cash reserves to pay out inaugural dividends to their shareholders, with their shared managing director alone to reap $3.12 million.

Tribune Resources Ltd intersects thick zones of gold in Ghana

Highlight assays from the program include: - 13 metres at 4.87g/t gold from 7 metres; - 13 metres @ 1.97g/t gold from 93 metres; and - 15 metres @ 2.18g/t gold from 36 metres. The Japa concession lies within the eastern portion of the Kumasi Basin of the Proterozoic Birimian Supergroup of West Africa. There are no lithological controls on gold mineralization at the Adiembra prospect. Gold is found within all rocks.

Big contract win for Barminco

Mining contractor Barminco has won a $275 million contract to provide its services to the Northern Star Resources-majority owned Kundana gold mines in the Goldfields.

NST: Kundana Update


Torian Resources drills 11.28 grams per tonne gold in WA

Torian Resources Ltd (ASX:TNR) is continuing a 4 phase drilling program at its Zuleika JV Project in the Goldfields region of Western Australia which has found high grade gold. The results from targets 4 to 9 of phase 1 rotary air blast drilling have now been received. Drilling at target 5 located a saprock gold target containing 4 metres at 11.28 g/t gold. Field inspection of this hole showed mineralisation in a quartz veined sheared felsic volcanics.

Half Year Accounts


Securities Trading Policy


Results of Meeting



Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...